DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT

This adverse event was reported 779 times

These drugs are most commonly taken by patients reporting DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT:

# Drug Count
0 RITUXIMAB 443
1 CYCLOPHOSPHAMIDE 414
2 DOXORUBICIN 389
3 PREDNISONE 319
4 DEXAMETHASONE 187
5 DEXAMETHASONE 1.5 MG 187
6 CYTARABINE 150
7 ETOPOSIDE 142
8 DOXORUBICIN HYDROCHLORIDE 137
9 PREDNISOLONE 136
See all common drugs associated with DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT

DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 POLATUZUMAB VEDOTIN 44 0.0549
1 DOXORUBICIN 389 0.0092
2 IFOSFAMIDE 80 0.0072
3 VINCRISTINE SULFATE 112 0.0070
4 ETOPOSIDE PHOSPHATE 5 0.0057
5 DOXORUBICIN HYDROCHLORIDE 137 0.0056
6 COPANLISIB 1 0.0055
7 PLATINUM 1 0.0048
8 CYTARABINE 150 0.0047
9 CYCLOPHOSPHAMIDE 414 0.0046
See all drugs enriched for association with DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT

DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD20-directed Cytolytic Antibody [EPC] 447 0.0036
1 Topoisomerase Inhibitor [EPC] 142 0.0035
2 Alkylating Drug [EPC] 440 0.0031
3 Platinum-based Drug [EPC] 222 0.0016
4 Echinocandin Antifungal [EPC] 4 0.0012
5 Hematopoietic Stem Cell Mobilizer [EPC] 1 0.0012
6 Nucleoside Metabolic Inhibitor [EPC] 153 0.0010
7 Corticosteroid [EPC] 507 0.0007
8 Antiprotozoal [EPC] 4 0.0006
9 Monobactam Antibacterial [EPC] 1 0.0006
See all drug classes enriched for association with DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT